BioCryst Pharmaceuticals, Inc. (BCRX)
USD 6.8
(-7.23%)
USD 6.8
(-7.23%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 516.96 Million USD | -6.01% |
| 2022 | 550 Million USD | -6.49% |
| 2021 | 588.15 Million USD | 75.72% |
| 2020 | 334.71 Million USD | 90.96% |
| 2019 | 175.28 Million USD | 19.37% |
| 2018 | 146.84 Million USD | -17.62% |
| 2017 | 178.25 Million USD | 98.4% |
| 2016 | 89.84 Million USD | -27.87% |
| 2015 | 124.55 Million USD | -9.0% |
| 2014 | 136.87 Million USD | 180.1% |
| 2013 | 48.86 Million USD | -14.93% |
| 2012 | 57.43 Million USD | -30.13% |
| 2011 | 82.2 Million USD | -25.65% |
| 2010 | 110.56 Million USD | -22.24% |
| 2009 | 142.19 Million USD | 67.89% |
| 2008 | 84.69 Million USD | -40.66% |
| 2007 | 142.71 Million USD | 108.39% |
| 2006 | 68.48 Million USD | -31.0% |
| 2005 | 99.24 Million USD | 205.68% |
| 2004 | 32.46 Million USD | 7.88% |
| 2003 | 30.09 Million USD | -27.13% |
| 2002 | 41.3 Million USD | -30.11% |
| 2001 | 59.09 Million USD | -16.56% |
| 2000 | 70.82 Million USD | -3.51% |
| 1999 | 73.4 Million USD | 152.23% |
| 1998 | 29.1 Million USD | 9.81% |
| 1997 | 26.5 Million USD | -28.57% |
| 1996 | 37.1 Million USD | 183.21% |
| 1995 | 13.1 Million USD | 2.34% |
| 1994 | 12.8 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 467.89 Million USD | -9.49% |
| 2024 Q2 | 472.41 Million USD | 0.97% |
| 2024 Q3 | 491.25 Million USD | 3.99% |
| 2023 Q1 | 509.73 Million USD | -7.32% |
| 2023 Q3 | -685.51 Million USD | -229.37% |
| 2023 Q2 | 529.88 Million USD | 3.95% |
| 2023 FY | 516.96 Million USD | -6.01% |
| 2023 Q4 | 516.96 Million USD | 175.41% |
| 2022 Q4 | 550 Million USD | -1.54% |
| 2022 FY | 550 Million USD | -6.49% |
| 2022 Q2 | 510.53 Million USD | -3.26% |
| 2022 Q3 | 558.59 Million USD | 9.41% |
| 2022 Q1 | 527.72 Million USD | -10.27% |
| 2021 FY | 588.15 Million USD | 75.72% |
| 2021 Q1 | 284.43 Million USD | -15.02% |
| 2021 Q2 | 277.28 Million USD | -2.51% |
| 2021 Q3 | 265.76 Million USD | -4.15% |
| 2021 Q4 | 588.15 Million USD | 121.31% |
| 2020 Q2 | 214.7 Million USD | 57.19% |
| 2020 FY | 334.71 Million USD | 90.96% |
| 2020 Q1 | 136.58 Million USD | -22.07% |
| 2020 Q3 | 176.22 Million USD | -17.92% |
| 2020 Q4 | 334.71 Million USD | 89.94% |
| 2019 FY | 175.28 Million USD | 19.37% |
| 2019 Q2 | 116.34 Million USD | -18.26% |
| 2019 Q3 | 90.5 Million USD | -22.21% |
| 2019 Q4 | 175.28 Million USD | 93.68% |
| 2019 Q1 | 142.33 Million USD | -3.07% |
| 2018 Q3 | 168.3 Million USD | 23.17% |
| 2018 FY | 146.84 Million USD | -17.62% |
| 2018 Q4 | 146.84 Million USD | -12.75% |
| 2018 Q2 | 136.64 Million USD | -12.05% |
| 2018 Q1 | 155.37 Million USD | -12.84% |
| 2017 FY | 178.25 Million USD | 98.4% |
| 2017 Q4 | 178.25 Million USD | -6.91% |
| 2017 Q3 | 191.49 Million USD | 68.7% |
| 2017 Q2 | 113.5 Million USD | -12.36% |
| 2017 Q1 | 129.51 Million USD | 44.15% |
| 2016 Q4 | 89.84 Million USD | -1.81% |
| 2016 FY | 89.84 Million USD | -27.87% |
| 2016 Q2 | 82.21 Million USD | -20.09% |
| 2016 Q3 | 91.5 Million USD | 11.29% |
| 2016 Q1 | 102.88 Million USD | -17.4% |
| 2015 FY | 124.55 Million USD | -9.0% |
| 2015 Q1 | 129.86 Million USD | -5.12% |
| 2015 Q3 | 138.95 Million USD | -7.47% |
| 2015 Q2 | 150.18 Million USD | 15.64% |
| 2015 Q4 | 124.55 Million USD | -10.36% |
| 2014 Q3 | 137.12 Million USD | -3.42% |
| 2014 FY | 136.87 Million USD | 180.1% |
| 2014 Q2 | 141.97 Million USD | 227.23% |
| 2014 Q1 | 43.38 Million USD | -11.21% |
| 2014 Q4 | 136.87 Million USD | -0.18% |
| 2013 Q3 | 53.2 Million USD | 33.29% |
| 2013 Q4 | 48.86 Million USD | -8.16% |
| 2013 Q2 | 39.91 Million USD | -14.89% |
| 2013 Q1 | 46.89 Million USD | -18.35% |
| 2013 FY | 48.86 Million USD | -14.93% |
| 2012 Q1 | 80.08 Million USD | -2.58% |
| 2012 Q2 | 76.23 Million USD | -4.81% |
| 2012 Q3 | 64.09 Million USD | -15.93% |
| 2012 Q4 | 57.43 Million USD | -10.38% |
| 2012 FY | 57.43 Million USD | -30.13% |
| 2011 Q1 | 122.76 Million USD | 12.17% |
| 2011 Q2 | 108.41 Million USD | -11.69% |
| 2011 FY | 82.2 Million USD | -25.65% |
| 2011 Q3 | 92.51 Million USD | -14.67% |
| 2011 Q4 | 82.2 Million USD | -11.14% |
| 2010 Q2 | 116.1 Million USD | -6.86% |
| 2010 FY | 110.56 Million USD | -22.24% |
| 2010 Q1 | 124.65 Million USD | -12.33% |
| 2010 Q4 | 109.44 Million USD | -1.71% |
| 2010 Q3 | 111.35 Million USD | -4.09% |
| 2009 Q2 | 64.69 Million USD | -10.89% |
| 2009 FY | 142.19 Million USD | 67.89% |
| 2009 Q3 | 60.58 Million USD | -6.35% |
| 2009 Q4 | 142.19 Million USD | 134.68% |
| 2009 Q1 | 72.6 Million USD | -14.27% |
| 2008 Q4 | 84.69 Million USD | -14.76% |
| 2008 FY | 84.69 Million USD | -40.66% |
| 2008 Q1 | 129.14 Million USD | -9.51% |
| 2008 Q2 | 107.64 Million USD | -16.64% |
| 2008 Q3 | 99.35 Million USD | -7.71% |
| 2007 Q2 | 78.42 Million USD | 15.47% |
| 2007 Q1 | 67.91 Million USD | -0.83% |
| 2007 FY | 142.71 Million USD | 108.39% |
| 2007 Q4 | 142.71 Million USD | 1.11% |
| 2007 Q3 | 141.15 Million USD | 79.98% |
| 2006 FY | 68.48 Million USD | -31.0% |
| 2006 Q4 | 68.48 Million USD | -14.6% |
| 2006 Q1 | 102.22 Million USD | 3.0% |
| 2006 Q2 | 91.87 Million USD | -10.12% |
| 2006 Q3 | 80.19 Million USD | -12.71% |
| 2005 Q2 | 43.42 Million USD | -12.25% |
| 2005 Q4 | 99.24 Million USD | 160.13% |
| 2005 FY | 99.24 Million USD | 205.68% |
| 2005 Q1 | 49.48 Million USD | 52.42% |
| 2005 Q3 | 38.15 Million USD | -12.14% |
| 2004 FY | 32.46 Million USD | 7.88% |
| 2004 Q1 | 45.95 Million USD | 52.69% |
| 2004 Q4 | 32.46 Million USD | -14.3% |
| 2004 Q2 | 41.76 Million USD | -9.11% |
| 2004 Q3 | 37.88 Million USD | -9.29% |
| 2003 Q4 | 30.09 Million USD | -6.65% |
| 2003 Q3 | 32.23 Million USD | -9.8% |
| 2003 Q2 | 35.74 Million USD | -7.32% |
| 2003 Q1 | 38.56 Million USD | -6.63% |
| 2003 FY | 30.09 Million USD | -27.13% |
| 2002 Q2 | 47.87 Million USD | -9.96% |
| 2002 FY | 41.3 Million USD | -30.11% |
| 2002 Q3 | 44.09 Million USD | -7.91% |
| 2002 Q1 | 53.17 Million USD | -10.03% |
| 2002 Q4 | 41.3 Million USD | -6.33% |
| 2001 Q2 | 65.54 Million USD | -3.71% |
| 2001 FY | 59.09 Million USD | -16.56% |
| 2001 Q3 | 62.84 Million USD | -4.12% |
| 2001 Q4 | 59.09 Million USD | -5.97% |
| 2001 Q1 | 68.06 Million USD | -3.89% |
| 2000 Q3 | 72.37 Million USD | -2.69% |
| 2000 Q4 | 70.82 Million USD | -2.14% |
| 2000 Q1 | 75.82 Million USD | 3.31% |
| 2000 FY | 70.82 Million USD | -3.51% |
| 2000 Q2 | 74.37 Million USD | -1.91% |
| 1999 Q4 | 73.4 Million USD | 178.03% |
| 1999 FY | 73.4 Million USD | 152.23% |
| 1999 Q1 | 26.7 Million USD | -8.25% |
| 1999 Q2 | 26.5 Million USD | -0.75% |
| 1999 Q3 | 26.4 Million USD | -0.38% |
| 1998 FY | 29.1 Million USD | 9.81% |
| 1998 Q1 | 24.5 Million USD | -7.55% |
| 1998 Q2 | 21.3 Million USD | -13.06% |
| 1998 Q3 | 24.5 Million USD | 15.02% |
| 1998 Q4 | 29.1 Million USD | 18.78% |
| 1997 Q2 | 32.3 Million USD | -5.56% |
| 1997 Q4 | 26.5 Million USD | -10.77% |
| 1997 Q3 | 29.7 Million USD | -8.05% |
| 1997 Q1 | 34.2 Million USD | -7.82% |
| 1997 FY | 26.5 Million USD | -28.57% |
| 1996 Q3 | 35.4 Million USD | 79.7% |
| 1996 Q2 | 19.7 Million USD | 3.14% |
| 1996 Q1 | 19.1 Million USD | 45.8% |
| 1996 Q4 | 37.1 Million USD | 4.8% |
| 1996 FY | 37.1 Million USD | 183.21% |
| 1995 Q4 | 13.1 Million USD | -11.49% |
| 1995 FY | 13.1 Million USD | 2.34% |
| 1995 Q1 | 9.7 Million USD | -24.22% |
| 1995 Q2 | 16.9 Million USD | 74.23% |
| 1995 Q3 | 14.8 Million USD | -12.43% |
| 1994 Q3 | 14.7 Million USD | -2.0% |
| 1994 Q4 | 12.8 Million USD | -12.93% |
| 1994 FY | 12.8 Million USD | 0.0% |
| 1994 Q2 | 15 Million USD | -12.28% |
| 1994 Q1 | 17.1 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 65.26% |
| Alkermes plc | 2.13 Billion USD | 75.8% |
| Agenus Inc. | 313.91 Million USD | -64.683% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 86.502% |
| Aptorum Group Limited | 20.64 Million USD | -2404.64% |
| Ardelyx, Inc. | 297.57 Million USD | -73.722% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 32.472% |
| Bicycle Therapeutics plc | 595.34 Million USD | 13.166% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -601.419% |
| ChromaDex Corporation | 54.96 Million USD | -840.543% |
| Chimerix, Inc. | 212.77 Million USD | -142.962% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -1728.498% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -17.233% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 76.813% |
| Precision BioSciences, Inc. | 159.78 Million USD | -223.543% |
| Dyadic International, Inc. | 8.21 Million USD | -6189.636% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -1528.733% |
| Fortress Biotech, Inc. | 167.52 Million USD | -208.585% |
| Lantern Pharma Inc. | 43.64 Million USD | -1084.395% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -220.422% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -3463.608% |
| Incyte Corporation | 6.78 Billion USD | 92.378% |
| IO Biotech, Inc. | 150.71 Million USD | -242.998% |
| Jaguar Health, Inc. | 50.76 Million USD | -918.38% |
| Novavax, Inc. | 1.85 Billion USD | 72.137% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -35.897% |
| Opthea Limited | 188.79 Million USD | -173.826% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 37.945% |
| ContextLogic Inc. | 423 Million USD | -22.213% |
| MiMedx Group, Inc. | 239.04 Million USD | -116.259% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -197.572% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -9899.805% |
| NextCure, Inc. | 129.41 Million USD | -299.45% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -858.256% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -1307.498% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -1500.446% |
| Vaxcyte, Inc. | 1.4 Billion USD | 63.282% |
| PDS Biotechnology Corporation | 59.39 Million USD | -770.448% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 19.294% |
| Pharming Group N.V. | 462.85 Million USD | -11.69% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -1236.505% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 17.754% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -2631.816% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -2631.816% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -212.703% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -1041.52% |
| Acelyrin, Inc. | 742.69 Million USD | 30.394% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -7748.754% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -7973.715% |
| Summit Therapeutics Inc. | 202.94 Million USD | -154.724% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -595.082% |
| Senti Biosciences, Inc. | 119.48 Million USD | -332.66% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -126.397% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -207.396% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -6156.323% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -10729.181% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -10.181% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -318.073% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -88.02% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -9.331% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -5015.883% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -141.0% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -45561.431% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -24.917% |
| Immix Biopharma, Inc. | 19.92 Million USD | -2494.509% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -39.709% |
| MEI Pharma, Inc. | 41.37 Million USD | -1149.45% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -1495.26% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -51.691% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -340.998% |
| Fortress Biotech, Inc. | 167.52 Million USD | -208.585% |
| Precigen, Inc. | 151.04 Million USD | -242.26% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -1419.666% |
| AlloVir, Inc. | 190.79 Million USD | -170.949% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -37.325% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -2.122% |
| ImmuCell Corporation | 43.8 Million USD | -1080.056% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 20.384% |
| Onconetix, Inc. | 88.82 Million USD | -482.022% |
| PureTech Health plc | 693.97 Million USD | 25.507% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -429.211% |
| Elevation Oncology, Inc. | 89.09 Million USD | -480.261% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -8235.376% |
| Seer, Inc. | 436.26 Million USD | -18.496% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -533.553% |
| Innoviva, Inc. | 1.24 Billion USD | 58.427% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -290.385% |
| ESSA Pharma Inc. | 149.12 Million USD | -246.669% |
| GlycoMimetics, Inc. | 45.31 Million USD | -1040.777% |
| GT Biopharma, Inc. | 14.1 Million USD | -3564.044% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -67.902% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -113.882% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -9.547% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -919.705% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -442.957% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -81750.827% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 8.719% |
| Aptose Biosciences Inc. | 12.92 Million USD | -3900.451% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -2237.675% |
| Soligenix, Inc. | 9.79 Million USD | -5176.542% |
| Century Therapeutics, Inc. | 360.69 Million USD | -43.325% |
| Kura Oncology, Inc. | 448.93 Million USD | -15.153% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -89.955% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -2889.072% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -366.102% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -151.99% |
| Autolus Therapeutics plc | 375.38 Million USD | -37.716% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -105.44% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -45.547% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -952.186% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 21.807% |
| GRI Bio, Inc. | 2.95 Million USD | -17388.498% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -4774.578% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -203.176% |
| IGM Biosciences, Inc. | 423.41 Million USD | -22.094% |
| INmune Bio, Inc. | 57 Million USD | -806.931% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -132.335% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -515.859% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -1879.411% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -7410.466% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -587.209% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -251.057% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -212.355% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 17.891% |
| Verastem, Inc. | 149.71 Million USD | -245.289% |
| Abeona Therapeutics Inc. | 64 Million USD | -707.725% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -0.938% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -234.695% |
| Histogen Inc. | 19.07 Million USD | -2610.428% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -2182.367% |
| Surrozen, Inc. | 46.08 Million USD | -1021.875% |
| Organovo Holdings, Inc. | 6.34 Million USD | -8042.385% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -11898.273% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -258.933% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -4280.275% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -586.826% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -5968.14% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -42.425% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -2757.017% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -20.391% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -3999.044% |
| Apollomics, Inc. | 55.38 Million USD | -833.36% |
| Amarin Corporation plc | 831.68 Million USD | 37.842% |
| Mesoblast Limited | 669.15 Million USD | 22.744% |
| Turnstone Biologics Corp. | 112.81 Million USD | -358.237% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 10.212% |
| Synaptogenix, Inc. | 31.11 Million USD | -1561.521% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -4142.942% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 5.675% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -8703.423% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -6938.105% |
| Exelixis, Inc. | 2.94 Billion USD | 82.43% |
| Better Therapeutics, Inc. | 22.94 Million USD | -2153.236% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -41.812% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 34.457% |
| NLS Pharmaceutics AG | 1.84 Million USD | -27894.613% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -6379.305% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -3417.931% |
| Gritstone bio, Inc. | 177.76 Million USD | -190.804% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -442.0% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -2794.145% |
| Avid Bioservices, Inc. | 336.55 Million USD | -53.603% |
| Insmed Incorporated | 1.32 Billion USD | 61.126% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -5269.147% |
| MediWound Ltd. | 66.45 Million USD | -677.863% |
| OmniAb, Inc. | 401.98 Million USD | -28.602% |
| Alector, Inc. | 621.82 Million USD | 16.864% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -44.161% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -9512.495% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -811.875% |
| Zai Lab Limited | 1.03 Billion USD | 50.115% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -8.048% |
| Aura Biosciences, Inc. | 255.07 Million USD | -102.67% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 31.075% |
| Immunic, Inc. | 54.29 Million USD | -852.062% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -94.182% |
| Veracyte, Inc. | 1.13 Billion USD | 54.566% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -4272.575% |
| FibroGen, Inc. | 423.52 Million USD | -22.06% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -14615.628% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -10814.146% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -9421.357% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 95.463% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -5771.21% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 0.095% |
| TG Therapeutics, Inc. | 329.58 Million USD | -56.851% |
| Galecto, Inc. | 38.22 Million USD | -1252.343% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -1702.762% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 88.135% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -119.605% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -1980.992% |
| XBiotech Inc. | 227.24 Million USD | -127.492% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -442.0% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -262.525% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -80.808% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -304.289% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -35.33% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 65.328% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -41.694% |
| Vaxxinity, Inc. | 44.35 Million USD | -1065.558% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -2677.961% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -69.467% |
| NexImmune, Inc. | 8.59 Million USD | -5915.395% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -4724.553% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -2918.323% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 98.437% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -2233.786% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -131688.459% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -198.254% |
| Ainos, Inc. | 31.84 Million USD | -1523.526% |
| Pluri Inc. | 39.52 Million USD | -1207.866% |
| Prothena Corporation plc | 696.38 Million USD | 25.765% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -82.92% |
| Celularity Inc. | 143.88 Million USD | -259.277% |
| Rallybio Corporation | 115.62 Million USD | -347.12% |
| Cue Biopharma, Inc. | 61.53 Million USD | -740.176% |
| MeiraGTx Holdings plc | 458.16 Million USD | -12.832% |
| Omeros Corporation | 378.26 Million USD | -36.665% |
| Humacyte, Inc. | 128.22 Million USD | -303.173% |
| Immunocore Holdings plc | 597 Million USD | 13.407% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -1553.796% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -654.356% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 50.731% |
| CalciMedica, Inc. | 12.18 Million USD | -4142.593% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -103.808% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -202.479% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -66.206% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 8.551% |
| Pulmatrix, Inc. | 33.95 Million USD | -1422.351% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -1804.369% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -267.008% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 60.264% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -297.084% |
| Cytokinetics, Incorporated | 824.31 Million USD | 37.286% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -2347.38% |
| Nutriband Inc. | 7.51 Million USD | -6777.071% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -554.761% |
| Vor Biopharma Inc. | 209.82 Million USD | -146.373% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 92.842% |
| Evogene Ltd. | 51.1 Million USD | -911.644% |
| ProKidney Corp. | 420.55 Million USD | -22.924% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -842.79% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -5330.094% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 5.385% |
| CorMedix Inc. | 82.05 Million USD | -529.978% |
| BioLineRx Ltd. | 63.92 Million USD | -708.698% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -28.416% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -1733.191% |
| Atai Life Sciences N.V. | 293.47 Million USD | -76.149% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -216.902% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -305.72% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 8.019% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -434.497% |
| MediciNova, Inc. | 66.26 Million USD | -680.082% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -487.802% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -11484.888% |
| GeoVax Labs, Inc. | 9.28 Million USD | -5468.758% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 12.117% |
| Biomea Fusion, Inc. | 199.92 Million USD | -158.574% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 72.837% |
| Mereo BioPharma Group plc | 66.49 Million USD | -677.395% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -6.569% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 15.651% |
| Absci Corporation | 234.48 Million USD | -120.471% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -6967.122% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -52.096% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -213.153% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 1.779% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -86.162% |
| Allakos Inc. | 243.61 Million USD | -112.208% |
| Imunon, Inc. | 21.91 Million USD | -2258.602% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -100.61% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 16.823% |
| BioAtla, Inc. | 119.65 Million USD | -332.031% |
| NLS Pharmaceutics AG | 1.84 Million USD | -27894.613% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -15954.658% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 19.581% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -438.865% |
| XOMA Corporation | 234.3 Million USD | -120.639% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -133.67% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -310.794% |
| aTyr Pharma, Inc. | 122.06 Million USD | -323.505% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -235.9% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 10.911% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -5.411% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -367.968% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -3310.576% |
| Akari Therapeutics, Plc | 4.35 Million USD | -11770.494% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -2934.278% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 70.174% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -16662.722% |
| UroGen Pharma Ltd. | 178.31 Million USD | -189.92% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -9.82% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -92926.102% |
| Orgenesis Inc. | 14.55 Million USD | -3452.501% |
| Entera Bio Ltd. | 11.76 Million USD | -4294.05% |
| GH Research PLC | 226.3 Million USD | -128.44% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -845.186% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -381.179% |
| Xencor, Inc. | 952.69 Million USD | 45.737% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -6541.511% |
| Replimune Group, Inc. | 487.72 Million USD | -5.995% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -6305.084% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 20.276% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -16662.722% |
| Portage Biotech Inc. | 7.77 Million USD | -6545.584% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -11484.888% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -86.665% |
| OncoCyte Corporation | 74.89 Million USD | -590.274% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -25325.329% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -8833.677% |
| Purple Biotech Ltd. | 44.3 Million USD | -1066.9% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -1414.857% |
| scPharmaceuticals Inc. | 94.47 Million USD | -447.169% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -2764.845% |
| HilleVax, Inc. | 344.43 Million USD | -50.09% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -16177.078% |
| Tharimmune, Inc. | 10.94 Million USD | -4622.652% |
| Genprex, Inc. | 10.67 Million USD | -4744.717% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -4.185% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -437.09% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -21209.151% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -12310.691% |
| OKYO Pharma Limited | 1.54 Million USD | -33441.301% |
| Savara Inc. | 177.56 Million USD | -191.14% |
| Curis, Inc. | 77.28 Million USD | -568.927% |
| Daré Bioscience, Inc. | 21.28 Million USD | -2329.07% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -708.397% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -6293.272% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -2568.732% |
| BeiGene, Ltd. | 5.8 Billion USD | 91.095% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -4148.172% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 75.248% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -44.422% |
| Erasca, Inc. | 395.29 Million USD | -30.778% |
| bluebird bio, Inc. | 619.16 Million USD | 16.506% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -11857.342% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 92.444% |
| DBV Technologies S.A. | 182.98 Million USD | -182.513% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -11857.342% |
| Moderna, Inc. | 18.42 Billion USD | 97.194% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -2737.789% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -4361.937% |
| Molecular Templates, Inc. | 35.38 Million USD | -1361.041% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -273.891% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 34.472% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -70.19% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -397.335% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -11.024% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -64.933% |
| MacroGenics, Inc. | 306.82 Million USD | -68.49% |
| RenovoRx, Inc. | 1.46 Million USD | -35163.302% |
| Adicet Bio, Inc. | 207.29 Million USD | -149.384% |
| Prime Medicine, Inc. | 193.85 Million USD | -166.679% |
| Aditxt, Inc. | 44.57 Million USD | -1059.667% |
| Adagene Inc. | 115.72 Million USD | -346.699% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -11506.153% |
| Quantum-Si incorporated | 298.25 Million USD | -73.331% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 65.245% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -6605.821% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -47.164% |
| SciSparc Ltd. | 11.18 Million USD | -4523.144% |
| Vericel Corporation | 353.65 Million USD | -46.176% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -4133.002% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -808.532% |
| Generation Bio Co. | 374.75 Million USD | -37.945% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -102.995% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -226.02% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -51.439% |
| Invivyd, Inc. | 229.18 Million USD | -125.568% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 38.747% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -4148.067% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -183.437% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -2431.14% |
| 2seventy bio, Inc. | 565.42 Million USD | 8.572% |
| ADMA Biologics, Inc. | 329.18 Million USD | -57.044% |
| Clene Inc. | 52.34 Million USD | -887.677% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -780.167% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -297.986% |
| GeoVax Labs, Inc. | 9.28 Million USD | -5468.758% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 20.918% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -398.942% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -296.484% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -429.933% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -628.143% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -113.133% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 73.626% |
| Evaxion Biotech A/S | 12.88 Million USD | -3910.981% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -105.094% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 31.318% |
| Trevena, Inc. | 40.6 Million USD | -1173.144% |
| Surrozen, Inc. | 46.08 Million USD | -1021.875% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -128.888% |
| Cingulate Inc. | 3.49 Million USD | -14706.515% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -3008.786% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -686.969% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -4324.275% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -92.524% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 30.976% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -310.638% |
| Clearmind Medicine Inc. | 4.32 Million USD | -11854.521% |
| Kronos Bio, Inc. | 213.27 Million USD | -142.387% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -223.537% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -5938.822% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -40.291% |
| Statera Biopharma, Inc. | 21.16 Million USD | -2341.982% |
| ImmunityBio, Inc. | 504.45 Million USD | -2.48% |
| Korro Bio, Inc. | 221.66 Million USD | -133.219% |
| Kineta, Inc. | 10.28 Million USD | -4928.305% |
| BioVie Inc. | 25.2 Million USD | -1950.749% |
| Codexis, Inc. | 136.56 Million USD | -278.556% |
| Celularity Inc. | 143.88 Million USD | -259.277% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 18.634% |
| Celcuity Inc. | 191.21 Million USD | -170.349% |
| Virax Biolabs Group Limited | 5.48 Million USD | -9326.749% |
| Cibus, Inc. | 544.41 Million USD | 5.042% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -310.631% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -2416.355% |
| IN8bio, Inc. | 33.7 Million USD | -1433.596% |
| Kodiak Sciences Inc. | 479.37 Million USD | -7.841% |
| Annexon, Inc. | 297.67 Million USD | -73.666% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -198.804% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -276.056% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -2362.535% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 82.711% |
| Eyenovia, Inc. | 28.77 Million USD | -1696.286% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -124.25% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -7056.146% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -748.505% |
| Arcellx, Inc. | 825.13 Million USD | 37.348% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -533.242% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -11.83% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -1581.171% |
| Moolec Science SA | 24.05 Million USD | -2049.407% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -66.694% |
| Geron Corporation | 394.07 Million USD | -31.183% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -408.269% |
| Royalty Pharma plc | 16.38 Billion USD | 96.844% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 13.111% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -7290.617% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -4198.216% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -128.683% |
| Humacyte, Inc. | 128.22 Million USD | -303.173% |
| Structure Therapeutics Inc. | 482.01 Million USD | -7.249% |
| 89bio, Inc. | 596.26 Million USD | 13.301% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -105.019% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -27843.784% |
| Genelux Corporation | 27.89 Million USD | -1753.368% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -478.236% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -125.325% |
| Notable Labs, Ltd. | 19.54 Million USD | -2545.515% |
| Liquidia Corporation | 120.43 Million USD | -329.258% |
| Mustang Bio, Inc. | 17.74 Million USD | -2813.764% |
| Immunovant, Inc. | 666.71 Million USD | 22.461% |
| Quantum-Si incorporated | 298.25 Million USD | -73.331% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -258.003% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -854.505% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -194.487% |
| Acasti Pharma Inc. | 73.3 Million USD | -605.266% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -11256.065% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -1879.411% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 46.418% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -9860.851% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -2169.259% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -901.802% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -186.102% |
| PepGen Inc. | 143.05 Million USD | -261.379% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -1252.696% |
| United Therapeutics Corporation | 7.16 Billion USD | 92.787% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -2594.605% |
| Solid Biosciences Inc. | 164.93 Million USD | -213.425% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -8703.423% |
| Immuneering Corporation | 102.58 Million USD | -403.936% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -11898.273% |
| Silo Pharma, Inc. | 7.74 Million USD | -6573.775% |
| Belite Bio, Inc | 94.64 Million USD | -446.227% |
| XOMA Corporation | 234.3 Million USD | -120.639% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -121.692% |
| Bionomics Limited | 27.64 Million USD | -1769.718% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -28.788% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -381.395% |
| uniQure N.V. | 831.68 Million USD | 37.842% |
| Cassava Sciences, Inc. | 151.66 Million USD | -240.861% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -11506.153% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -88.751% |
| Forte Biosciences, Inc. | 38.98 Million USD | -1226.219% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -12592.009% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -1303.6% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -7056.146% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -14615.628% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -4273.234% |
| Altimmune, Inc. | 210.64 Million USD | -145.423% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 33.542% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -381.395% |
| Compugen Ltd. | 121.33 Million USD | -326.064% |
| Peak Bio, Inc. | 2.59 Million USD | -19810.53% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -199.988% |
| Benitec Biopharma Inc. | 52.21 Million USD | -890.155% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -51.22% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -1386.671% |
| Zura Bio Limited | 100.84 Million USD | -412.638% |
| PolyPid Ltd. | 15.37 Million USD | -3262.998% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -333.379% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -1386.671% |
| Instil Bio, Inc. | 325.63 Million USD | -58.757% |
| argenx SE | 4.54 Billion USD | 88.619% |
| Immunome, Inc. | 148.54 Million USD | -248.027% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -229.536% |
| Verona Pharma plc | 308.12 Million USD | -67.777% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -494.487% |
| Shattuck Labs, Inc. | 159.56 Million USD | -223.983% |
| CervoMed Inc. | 9.97 Million USD | -5083.845% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -174.313% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -4439.515% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -188.153% |
| Moolec Science SA | 24.05 Million USD | -2049.407% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -8350.538% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -198.917% |
| AnaptysBio, Inc. | 452.38 Million USD | -14.273% |
| Design Therapeutics, Inc. | 289.64 Million USD | -78.482% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -609.866% |
| NeurAxis, Inc. | 509.49 Thousand USD | -101364.579% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -9441.528% |
| Lumos Pharma, Inc. | 40.63 Million USD | -1172.11% |
| Achilles Therapeutics plc | 161.45 Million USD | -220.186% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -494.487% |
| 180 Life Sciences Corp. | 5.25 Million USD | -9729.116% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -634.028% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -5938.822% |
| Nutriband Inc. | 7.51 Million USD | -6777.071% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -102.979% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -159.387% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -578.318% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -792.603% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 1.819% |
| Palisade Bio, Inc. | 14.05 Million USD | -3578.907% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -145.826% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 64.585% |
| Neurogene Inc. | 222.57 Million USD | -132.265% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 20.052% |
| AEON Biopharma, Inc. | 6.84 Million USD | -7452.374% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -14.11% |
| Sesen Bio, Inc. | 189.17 Million USD | -173.272% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -90.152% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -3670.164% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 33.753% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -93.622% |
| Athira Pharma, Inc. | 160.24 Million USD | -222.606% |
| Vaccinex, Inc. | 3.63 Million USD | -14137.4% |
| HCW Biologics Inc. | 28.51 Million USD | -1713.026% |
| XOMA Corporation | 234.3 Million USD | -120.639% |
| Nektar Therapeutics | 398.03 Million USD | -29.879% |
| Arvinas, Inc. | 1.3 Billion USD | 60.374% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -2934.278% |
| Merus N.V. | 458.49 Million USD | -12.752% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -152.958% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -186.875% |
| Rezolute, Inc. | 132.73 Million USD | -289.462% |
| Clene Inc. | 52.34 Million USD | -887.677% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -3363.979% |
| BeyondSpring Inc. | 24.8 Million USD | -1983.844% |
| Synlogic, Inc. | 75.55 Million USD | -584.262% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -4258.118% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -5420.718% |
| Peak Bio, Inc. | 2.59 Million USD | -19810.53% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -195.688% |
| Krystal Biotech, Inc. | 818.35 Million USD | 36.829% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -115.008% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 28.773% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -14351.631% |
| MannKind Corporation | 475.19 Million USD | -8.788% |
| Ikena Oncology, Inc. | 192.09 Million USD | -169.121% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -3765.41% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -343.594% |
| Gossamer Bio, Inc. | 311.91 Million USD | -65.737% |
| CohBar, Inc. | 16.36 Million USD | -3058.808% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -1370.182% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -6967.122% |
| Legend Biotech Corporation | 1.84 Billion USD | 72.035% |
| Mural Oncology plc | 301.74 Million USD | -71.323% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -1556.127% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -9000.76% |
| Disc Medicine, Inc. | 367.99 Million USD | -40.48% |
| Champions Oncology, Inc. | 26.13 Million USD | -1878.264% |
| REGENXBIO Inc. | 573.97 Million USD | 9.933% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -18989.504% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -234.849% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -4181.037% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -52.031% |
| Vaxart, Inc. | 91.83 Million USD | -462.953% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -762.982% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -248.527% |
| Cellectis S.A. | 334.27 Million USD | -54.653% |
| Longeveron Inc. | 12.17 Million USD | -4145.032% |
| Repare Therapeutics Inc. | 253.9 Million USD | -103.607% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 84.165% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -157.39% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 75.248% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -31712.923% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -86.15% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -216.963% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -272.6% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -1925.547% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 97.726% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 55.2% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -4133.002% |
| Veru Inc. | 50.59 Million USD | -921.742% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -1034.854% |
| Cingulate Inc. | 3.49 Million USD | -14706.515% |
| Passage Bio, Inc. | 150.54 Million USD | -243.392% |
| Context Therapeutics Inc. | 16.06 Million USD | -3118.381% |
| Exicure, Inc. | 11.58 Million USD | -4364.249% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -37.472% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -219.818% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -2858.791% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -55.362% |
| Nuvalent, Inc. | 732.38 Million USD | 29.414% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -3359.296% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -477.261% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -3542.872% |
| OmniAb, Inc. | 401.98 Million USD | -28.602% |
| Anew Medical, Inc. | 19.45 Million USD | -2557.079% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -1834.256% |
| Lipocine Inc. | 23 Million USD | -2147.547% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -269.767% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -69.182% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -515.859% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -325.341% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -6414.934% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 41.406% |
| Ocugen, Inc. | 64.54 Million USD | -700.905% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -315.092% |
| Q32 Bio Inc. | 306.11 Million USD | -68.876% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -12185.171% |
| Alumis Inc. Common Stock | 89.61 Million USD | -476.887% |
| Equillium, Inc. | 50.53 Million USD | -923.075% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -587.493% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -1152.522% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -30294.161% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -1877.583% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -702.222% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -13770.253% |
| Dominari Holdings Inc. | 57.55 Million USD | -798.155% |
| Edesa Biotech, Inc. | 8.89 Million USD | -5714.787% |
| vTv Therapeutics Inc. | 11.01 Million USD | -4591.959% |
| Bio-Techne Corporation | 2.81 Billion USD | 81.624% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 44.835% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 36.292% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -86.181% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -1139.653% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 22.563% |
| Nkarta, Inc. | 378.88 Million USD | -36.442% |
| BioCardia, Inc. | 2.98 Million USD | -17206.997% |
| Iterum Therapeutics plc | 26.25 Million USD | -1868.696% |